{"analyses":[{"ciLowerLimit":"0.614","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.763","groupDescription":"Cough for Teff-high WT ITT population","groupIds":["OG001","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8816","paramType":"Hazard Ratio (HR)","paramValue":"1.041","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.419","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.309","groupDescription":"Cough for Teff-high WT ITT Population","groupIds":["OG000","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2995","paramType":"Hazard Ratio (HR)","paramValue":"0.741","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.616","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.422","groupDescription":"Dyspnea in Teff-high WT Population","groupIds":["OG001","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7578","paramType":"Hazard Ratio (HR)","paramValue":"0.936","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.694","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.560","groupDescription":"Dyspnea in Teff-high WT Population","groupIds":["OG000","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8470","paramType":"Hazard Ratio (HR)","paramValue":"1.041","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.383","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.133","groupDescription":"Pain in Chest in Teff-high WT Population","groupIds":["OG001","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1289","paramType":"Hazard Ratio (HR)","paramValue":"0.659","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.430","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.235","groupDescription":"Pain in Chest in Teff-high WT Population","groupIds":["OG000","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2381","paramType":"Hazard Ratio (HR)","paramValue":"0.729","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.685","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.732","groupDescription":"Arm and/or Shoulder Pain in Teff-high WT","groupIds":["OG001","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7163","paramType":"Hazard Ratio (HR)","paramValue":"1.090","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.420","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.145","groupDescription":"Arm and/or Shoulder Pain in Teff-high WT","groupIds":["OG000","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1502","paramType":"Hazard Ratio (HR)","paramValue":"0.693","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.713","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.430","groupDescription":"Cough in ITT-WT Population","groupIds":["OG001","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9568","paramType":"Hazard Ratio (HR)","paramValue":"1.010","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.619","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.284","groupDescription":"Cough in ITT-WT Population","groupIds":["OG000","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5377","paramType":"Hazard Ratio (HR)","paramValue":"0.891","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.685","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.163","groupDescription":"Dyspnea in ITT-WT Population","groupIds":["OG001","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.4012","paramType":"Hazard Ratio (HR)","paramValue":"0.893","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.809","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.363","groupDescription":"Dyspnea in ITT-WT Population","groupIds":["OG000","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7149","paramType":"Hazard Ratio (HR)","paramValue":"1.050","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.786","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.422","groupDescription":"Arm and/or Shoulder Pain in ITT-WT","groupIds":["OG001","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7126","paramType":"Hazard Ratio (HR)","paramValue":"1.057","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.675","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.258","groupDescription":"Arm and/or Shoulder Pain in ITT-WT","groupIds":["OG000","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6053","paramType":"Hazard Ratio (HR)","paramValue":"0.921","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.576","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.194","groupDescription":"Pain in Chest in ITT-WT Population","groupIds":["OG001","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3134","paramType":"Hazard Ratio (HR)","paramValue":"0.829","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.633","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.309","groupDescription":"Pain in Chest in ITT-WT Population","groupIds":["OG000","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6115","paramType":"Hazard Ratio (HR)","paramValue":"0.910","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nUpper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG001","lowerLimit":"21.0","upperLimit":"NA","value":"NA"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"155"},{"groupId":"OG002","value":"129"}],"units":"Participants"}],"title":"Cough in Teff-high WT Population"},{"categories":[{"measurements":[{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nUpper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG000","lowerLimit":"5.6","upperLimit":"NA","value":"NA"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nUpper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG002","lowerLimit":"6.3","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"155"},{"groupId":"OG002","value":"129"}],"units":"Participants"}],"title":"Dyspnea in Teff-high WT Population"},{"categories":[{"measurements":[{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG001","lowerLimit":"22.2","upperLimit":"NA","value":"22.2"},{"comment":"Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG002","lowerLimit":"18.4","upperLimit":"NA","value":"18.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"155"},{"groupId":"OG002","value":"129"}],"units":"Participants"}],"title":"Chest Pain in Teff-high WT Population"},{"categories":[{"measurements":[{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nUpper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG000","lowerLimit":"18.3","upperLimit":"NA","value":"NA"},{"comment":"Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG001","lowerLimit":"12.5","upperLimit":"NA","value":"19.5"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nUpper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG002","lowerLimit":"12.7","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"155"},{"groupId":"OG002","value":"129"}],"units":"Participants"}],"title":"Arm and/or Shoulder Pain in Teff-high WT"},{"categories":[{"measurements":[{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nUpper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG001","lowerLimit":"21.0","upperLimit":"NA","value":"NA"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"356"},{"groupId":"OG002","value":"336"}],"units":"Participants"}],"title":"Cough in ITT-WT Population"},{"categories":[{"measurements":[{"comment":"Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG000","lowerLimit":"9.7","upperLimit":"NA","value":"21.9"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nUpper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG002","lowerLimit":"10.0","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"356"},{"groupId":"OG002","value":"336"}],"units":"Participants"}],"title":"Dyspnea in ITT-WT Population"},{"categories":[{"measurements":[{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nUpper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG000","lowerLimit":"18.3","upperLimit":"NA","value":"NA"},{"comment":"Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG001","lowerLimit":"15.2","upperLimit":"NA","value":"19.5"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"356"},{"groupId":"OG002","value":"336"}],"units":"Participants"}],"title":"Arm and/or Shoulder Pain in ITT-WT"},{"categories":[{"measurements":[{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nUpper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG001","lowerLimit":"22.2","upperLimit":"NA","value":"NA"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nUpper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG002","lowerLimit":"18.4","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"356"},{"groupId":"OG002","value":"336"}],"units":"Participants"}],"title":"Pain in Chest in ITT-WT Population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"356"},{"groupId":"OG002","value":"336"}],"units":"Participants"}],"description":"QLQ-LC13 Quality-of-Life Questionnaire Lung Cancer Module incorporates one multiple-item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The EORTC QLQ-LC13 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however, a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.","id":"OG001","title":"Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)"},{"description":"Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.","id":"OG002","title":"Arm C (Bevacizumab+Paclitaxel+Carboplatin)"}],"paramType":"MEDIAN","populationDescription":"Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 29 months","title":"TTD in Patient-Reported Lung Cancer Symptoms as Determined by EORTC Quality-of-Life Questionnaire-Core Lung Cancer Module 13 (QLQ-LC13) Score","type":"SECONDARY","unitOfMeasure":"Months"}